Trials / Recruiting
RecruitingNCT03819101
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,210 (estimated)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acetylsalicylic acid | 100mg |
| DRUG | Atorvastatin | 80 mg |
Timeline
- Start date
- 2019-06-06
- Primary completion
- 2042-03-01
- Completion
- 2042-03-01
- First posted
- 2019-01-28
- Last updated
- 2025-06-26
Locations
23 sites across 6 countries: Czechia, France, Italy, Slovakia, Switzerland, Tunisia
Source: ClinicalTrials.gov record NCT03819101. Inclusion in this directory is not an endorsement.